Summary of Study ST001815

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001148. The data can be accessed directly via it's Project DOI: 10.21228/M89Q5T This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001815
Study TitleMetabolic Markers of Methotrexate Response in Juvenile Idiopathic Arthritis
Study TypeClinical
Study SummaryPlasma from children with juvenile idiopathic arthritis collected pre-treatment and following 3 months of treatment with methotrexate were submitted for metabolomic profiling to the NIH West Coast Metabolomics Center.
University of Kansas
DepartmentPharmacy Practice
LaboratoryFunk Lab
Last Namefunk
First Nameryan
Address2106 Olathe Boulevard
Submit Date2021-05-18
Num Groups1
Total Subjects30
Num Males9
Num Females21
Analysis Type DetailGC/LC-MS
Release Date2021-06-17
Release Version1
ryan funk ryan funk application/zip

Select appropriate tab below to view additional metadata details:


Treatment ID:TR001905
Treatment Summary:Plasma samples were acquired from a single-center prospective cohort of JIA patients. The study included patients diagnosed with JIA requiring initiation of MTX for inadequately controlled disease without the need for biological therapy at initiation. Diagnosis of JIA was established based on the Edmonton 2001 International League of Associations of Rheumatology (ILAR) criteria for JIA. Patients were initiated on a standardized MTX dose of 15 mg/m2 weekly by subcutaneous or oral administration along with 1 mg folic acid daily. Concurrent medications allowed included nonsteroidal anti-inflammatory drugs (NSAIDs) and daily low-dose steroids (the lesser of 0.2 mg/kg/day or 10 mg). Intra-articular steroid injections (IASI) were allowed, however injected joints were counted as “active” at follow up to reduce the potential bias resulting from IASI.
Treatment Compound:Methotrexate
Treatment Route:Oral or Subcutaneous
Treatment Dose:15 mg/m^2
Treatment Doseduration:3 months